Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOXYLAMINE SUCCINATE vs Doxylamine
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Antagonist at histamine H1 receptors, producing sedative and antihistaminic effects; also possesses anticholinergic properties.
Doxylamine is a first-generation antihistamine with sedative properties. It acts as a competitive antagonist at histamine H1 receptors, thereby blocking the effects of histamine. It also possesses anticholinergic activity.
Temporary relief of insomnia,Temporary relief of allergic rhinitis symptoms,Temporary relief of common cold symptoms,Motion sickness prevention and treatment,Nausea and vomiting of pregnancy (off-label, with pyridoxine)
Insomnia (short-term use),Allergic rhinitis,Common cold symptoms (as a combination product),Nausea and vomiting of pregnancy (as a combination product with pyridoxine; off-label)
6.25 to 25 mg orally every 4 to 6 hours as needed, not to exceed 150 mg per day.
12.5–25 mg orally at bedtime for insomnia; 25 mg orally every 4–6 hours as needed for allergies (max 150 mg/day).
Terminal elimination half-life ranges from 10 to 12 hours in adults. In elderly patients, half-life may be prolonged (up to 15-18 hours) due to reduced renal clearance.
10-12 hours; prolonged in elderly and hepatic impairment.
Primarily hepatic via CYP450 enzymes (CYP2D6, CYP1A2, and others); undergoes N-demethylation and other oxidative pathways.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl <30 m L/min).
No specific dosage adjustment guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation and anticholinergic effects.
Not applicable; no FDA black box warning.
First trimester: Doxylamine succinate is a pregnancy category A antihistamine used for nausea and vomiting of pregnancy (NVP). Studies in pregnant women have not shown an increased risk of congenital malformations. Second and third trimesters: No evidence of fetal harm; safety established for use in NVP. No known teratogenic effects.
FDA Pregnancy Category A. No evidence of increased risk of fetal abnormalities in first trimester. In second and third trimesters, no known risks. However, use in late pregnancy may be associated with neonatal withdrawal symptoms or respiratory depression if used near term.
Doxylamine succinate is a first-generation antihistamine with strong sedative properties, commonly used as a sleep aid. Its anticholinergic effects can cause dry mouth, blurred vision, urinary retention, and constipation. Use with caution in elderly patients due to increased risk of falls, confusion, and anticholinergic toxicity. Avoid in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Onset of sedation occurs within 30 minutes; duration is 6-8 hours. Not recommended for chronic insomnia.
Doxylamine is a first-generation antihistamine with strong sedative properties, often used as a short-term sleep aid. Its anticholinergic effects can exacerbate conditions like urinary retention, glaucoma, and dementia. Avoid in elderly due to increased fall risk and confusion. Onset of sedation: 30-60 min; duration: 6-8 hours.
No interactions on record
"Doxylamine may increase the anticholinergic activities of Phenelzine."
"Doxylamine may increase the anticholinergic activities of Selegiline."
"Doxylamine may increase the anticholinergic activities of Rasagiline."
DOXYLAMINE SUCCINATE and Doxylamine are distinct pharmacological agents. DOXYLAMINE SUCCINATE belongs to the Antihistamine (Sedating) class and is primarily used for Temporary relief of insomniaTemporary relief of allergic rhinitis symptomsTemporary relief of common cold symptomsMotion sickness prevention and treatmentNausea and vomiting of pregnancy (off-label, with pyridoxine). Doxylamine belongs to the Antihistamine (Sedating) class and is primarily used for Insomnia (short-term use)Allergic rhinitisCommon cold symptoms (as a combination product)Nausea and vomiting of pregnancy (as a combination product with pyridoxine; off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. DOXYLAMINE SUCCINATE carries a safety status of Category C, whereas Doxylamine safety is classified as Category A/B. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Metabolized primarily by the liver, likely via hydroxylation and conjugation; specific cytochrome P450 enzymes not well characterized.
Renal excretion of metabolites (30-60% as conjugated metabolites, <5% unchanged). Fecal elimination is minor (<10%).
Renal (approximately 60% as unchanged drug and metabolites, primarily as N-desmethyldoxylamine and other metabolites); biliary/fecal (minor).
Approximately 80-90% bound to plasma proteins, primarily albumin.
Approximately 60-70%, primarily to albumin.
Apparent volume of distribution is 2.5-4.5 L/kg, indicating extensive tissue distribution.
2.5-3.5 L/kg; indicates extensive tissue distribution.
Oral bioavailability is approximately 70-80% due to first-pass metabolism.
Oral: ~70-80% due to first-pass metabolism.
No specific dose adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh class C).
Contraindicated in severe hepatic impairment (Child-Pugh C); for Child-Pugh A or B, use lowest effective dose and monitor closely for sedation and confusion.
Children 6-11 years: 3.125 to 6.25 mg orally every 4-6 hours, not to exceed 37.5 mg/day. Children 12 years and older: same as adult dosing.
For children ≥12 years: 25 mg orally every 4–6 hours as needed (max 150 mg/day). For children 6–11 years: 6.25 mg (half of a 12.5 mg tablet) every 4–6 hours (max 37.5 mg/day). Not recommended for children <6 years.
Initiate at the lowest effective dose (e.g., 6.25 mg) due to increased sensitivity and risk of anticholinergic effects, sedation, and falls. Maximum recommended dose: 100 mg per day.
Initiate with 6.25 mg (half of a 12.5 mg tablet) at bedtime; avoid chronic use due to increased risk of sedation, dizziness, and anticholinergic effects (e.g., confusion, urinary retention).
None.
Avoid alcohol and grapefruit juice as they may increase sedation and side effects. No significant food interactions.
Avoid alcohol and grapefruit juice; grapefruit may increase sedative effects. No significant food restrictions, but taking with a small snack may reduce GI upset. Caffeinated beverages should be limited during the day to minimize insomnia.
Doxylamine passes into breast milk in small amounts. The M/P ratio is not established. Single doses are considered compatible with breastfeeding; caution with chronic or high doses due to potential infant sedation or irritability.
Doxylamine is excreted into breast milk in small amounts; M/P ratio approximately 0.5–1.0. Considered compatible with breastfeeding at recommended doses. Monitor infant for drowsiness or irritability.
No dose adjustment required in pregnancy. Increased plasma volume may slightly dilute drug concentration, but clinical efficacy maintained. Maximum recommended dose for NVP is 40 mg per day (doxylamine succinate 10 mg plus pyridoxine 10 mg, up to 4 tablets daily).
No dose adjustment required. Pharmacokinetics unchanged in pregnancy. Usual adult dose of 25–50 mg orally at bedtime is appropriate. Avoid exceeding recommended doses due to increased sedation.
Take only at bedtime due to drowsiness.,Avoid alcohol and other CNS depressants.,Do not drive or operate machinery until you know how the drug affects you.,Notify your doctor if you have glaucoma, trouble urinating, or prostate problems.,May cause dry mouth; sugarless gum or candy can help.,Do not take for more than 7-10 days without consulting a doctor.
Take doxylamine only when you have at least 7-8 hours to sleep to avoid next-day drowsiness.,Do not combine with alcohol or other sedatives (e.g., benzodiazepines, opioids).,Avoid driving or operating heavy machinery until you know how this drug affects you.,Do not use for more than 7-10 consecutive days for insomnia; see a doctor if symptoms persist.,Report difficulty urinating, blurred vision, or rapid heartbeat immediately.